
## **Supplementary information**

## Open science in precision medicine for neurodegenerative diseases

In the format provided by the authors

## Supplementary Figure 1.



## Supplementary Box 1. Ethics declaration.

H.L.L. and M.A.N.'s participation in this project was part of a competitive contract awarded to DataTecnica LLC by the National Institutes of Health to support open science research. M.A.N. also currently serves on the scientific advisory board for Character Bio Inc and is a scientific founder at Neuron23 Inc and owns stock. S.E. is an employee of Neuron23 Inc and owns stock. P.J. is a government communications contractor at the National Institutes of Health and contributed as part of a personal services contract. S.B.C. and A.B.S. are federal government employees. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Services; project number ZO1 AG000534, as well as the National Institute of Neurological Disorders and Stroke. A.G.D-W is a private consultant to biotech companies advising on data, computational, and therapeutic strategy. A.G.D-W is a former employee of Vesalius Therapeutics and owns stock. P.H. is an employee of Alector and owns stock. S.P.S. is an employee of Sanofi and owns stock. ABS is a scientific advisory board member for Cajal Neurosciences.